Compared to wild-type AZIN1, edited AZIN1-S367G has stronger antizyme binding and inhibits antizyme-mediated degradation of ODC and cyclin D1, thereby facilitating entry into the cell cycle and increasing the malignancy of liver cancer cells97. Here, AZIN1 is linked to liver cancer.